Please find the session links next to their corresponding agenda item.
Prerecorded
Overview of Drug Law and Regulation
Alexandre Gapihan, Associate,Morgan, Lewis & Bockius LLP
Watch this session here.
The New Drug Approval Process: Basic Concepts
Nathan A. Beaton, Associate, Latham & Watkins LLP
Watch this session here.
Wednesday, April 27
11:00 AM
FDLI Welcome and Announcements
Enter this session: https://fdli.zoom.us/j/82411342305
11:05 AM – 12:15 PM
The New Drug Approval Process: New Drug Research and Development
Lee Rosebush, Partner, Baker Hostetler
Enter this session: https://fdli.zoom.us/j/82411342305
12:15 – 12:25 PM
Break
12:25 – 1:35 PM
The New Drug Approval Process: NDA Submission and Review
Charles G. Raver, Associate, Hyman, Phelps, & McNamara, PC
Enter this session: https://fdli.zoom.us/j/88278133348
1:35 – 1:40 PM
Break
1:40 – 2:50 PM
The Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues
Rebecca L. Dandeker, Partner, Morgan, Lewis & Bockius LLP
Enter this session: https://fdli.zoom.us/j/87964795613
2:50 – 3:00 PM
Break
3:00 – 4:10 PM
Post-Approval Issues
David L. Rosen, Partner, Foley & Lardner LLP
Enter this session: https://fdli.zoom.us/j/83397018482
4:10 – 4:20 PM
Break
4:20 – 5:20 PM
Biologics and Biosimilars
Emily Marden, Counsel, Sidley Austin LLP
Enter this session: https://fdli.zoom.us/j/86069125929